Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Healthy ExtractsHYEX 63 EV-to-EBITDA is -34.14 as of Aug. 13, 2026. GuruFocus rates HYEX with a GF Score™ of 63/100 and a GF Value™ of $1.62 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 734 Drug Manufacturers companies, Healthy Extracts ranks worse than 136239.65% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Healthy Extracts's enterprise value is $22.29 Mil.
Healthy Extracts's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was $-0.65 Mil. Therefore, Healthy Extracts's EV-to-EBITDA for today is -34.14.
The historical rank and industry rank for Healthy Extracts's EV-to-EBITDA or its related term are showing as below:
HYEX'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -850.87 Med: -9.59 Max: -0.24
Current: -34.14
During the past 12 years, the highest EV-to-EBITDA of Healthy Extracts was -0.24. The lowest was -850.87. And the median was -9.59.
HYEX's EV-to-EBITDA is ranked worse than 100% of 734
companies
in the Drug Manufacturers industry
Industry Median: 13.355
vs HYEX: -34.14
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Healthy Extracts's PE Ratio (TTM) for today is calculated as:
Healthy Extracts's share price for today is $1.35.
Healthy Extracts's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.059.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Healthy Extracts's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Healthy Extracts's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Healthy Extracts EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Healthy Extracts's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Healthy Extracts's EV-to-EBITDA falls into.
Healthy Extracts's current Enterprise Value is $22.29 Mil.
Healthy Extracts's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.65 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Healthy Extracts (HYEX) has a EV-to-EBITDA of -34.14 as of Aug. 13, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Healthy Extracts. According to the industry distribution chart, Healthy Extracts ranks #999999 out of 734 companies in the Drug Manufacturers industry.
Is Healthy Extracts' EV-to-EBITDA too high?
Healthy Extracts' current EV-to-EBITDA is -34.14. Based on the distribution chart, Healthy Extracts ranks #999999 out of 734 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Healthy Extracts has a GF Score™ of 63/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Healthy Extracts' EV-to-EBITDA compare to CABR and BFRI?
According to the Drug Manufacturers industry distribution chart, Healthy Extracts ranks #999999 out of 734 companies for EV-to-EBITDA. This places Healthy Extracts in the lower half of its industry. The industry median EV-to-EBITDA is 13.36. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 13.36, based on 734 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Healthy Extracts. For the Drug Manufacturers industry, the median EV-to-EBITDA is 13.36 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Healthy Extracts's current EV-to-EBITDA is -34.14. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Healthy Extracts stock overvalued right now?
Based on GuruFocus' analysis, Healthy Extracts (HYEX) is currently considered Modestly Undervalued. The stock's GF Value™ is $1.62, compared to a current price of $1.35 — trading 16.7% below its estimated fair value. The current EV-to-EBITDA is -34.14. Healthy Extracts' overall GF Score™ is 63/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Healthy Extracts (HYEX), the current EV-to-EBITDA is -34.14 as of Aug. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Healthy Extracts (HYEX) Overvalued in 2026?
Based on GuruFocus' analysis, Healthy Extracts stock appears to be undervalued.
The current stock price of $1.35 is trading 16.7% below its estimated GF Value™ of $1.62.
GuruFocus considers Healthy Extracts to be Modestly Undervalued.
Key valuation signals for HYEX:
EV-to-EBITDA: -34.14
GF Value™: $1.62 vs. price of $1.35 (16.7% below fair value)
No single metric tells the full story. See the HYEX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Healthy Extracts Inc through its subsidiaries is engaged in proprietary research and development of natural plant-based formulations, manufacturing, sales, and distribution of cardiovascular and neuro products that provide natural brain solutions. The company also provides superfruit supplements to support overall cholesterol, metabolic and cardiovascular health. Its products are distributed in the United States and Mexico. Its operating segment includes, Health Supplements and Corporate. The company generates maximum revenue from the Health Supplements segment.
63GF Score
Get the complete analysis for HYEX
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HYEX has been successfully added to your 
